HETEROCYCLIC COMPOUNDS AND USE THEREOF FOR PREVENTING OR TREATING BACTERIAL INFECTIONS Russian patent published in 2020 - IPC C07D471/08 A61K31/439 A61P31/04 

FIELD: medicine.

SUBSTANCE: invention relates to a compound of formula (B) applicable in medicine, including in a pharmaceutical composition and a kit:

where R¹ denotes carbon-bonded, unsubstituted or substituted with one or more T¹, an aromatic, saturated, completely or partially unsaturated 4-, 5- or 6-member heterocycle containing at least one nitrogen atom; -CN; -C(O)NHQ¹; -C(O)NHOQ¹; -C(O)NH-NHQ¹; -C(O)O-NHQ¹; -C(O)OQ¹; -(CH₂)_mOC(O)OQ¹; -(CH₂)_mOQ¹; -(CH₂)_mOC(O)Q¹; -(CH₂)_mOC(O)NQ¹Q²; -(CH₂)_m-NHC(O)Q¹; -(CH₂)_mNHS(O)₂Q¹; -(CH₂)_mNHS(O)₂NQ¹Q²; -(CH₂)_mNHC(O)OQ¹; -(CH₂)_mNHC(O)NQ¹Q²; -(CH₂)_mNHQ³; -(CH₂)_mNH-C(NHQ³)=NQ⁴; -(CH₂)_mNH-CH=NQ³; -C(NHQ³)=NQ⁴; R² denotes O or NOQ⁵; R³ stands for SO₃H, CFHCO₂H or CF₂CO₂H; Q¹ and Q² independently denote a hydrogen atom; -(CH₂)_pNHQ³; -(CH₂)_p-NH-C(NHQ³)=NQ⁴; (CH₂)_p-NH-CH=NQ³; (CH₂)_q-C(NHQ³)=NQ⁴; -(CH₂)_pOQ³; -(CH₂)_qCONHQ³; or Q¹ and Q², unsubstituted or substituted with one or more T², independently denote (C₁-C₃) alkyl; - (CH₂)_n-(4-, 5- or 6-member heterocycle); or Q¹, Q² and the nitrogen atom to which they are bonded form a saturated or partially unsaturated 4-, 5- or 6-member heterocycle containing 1, 2 or 3 heteroatoms; Q³ and Q⁴ independently denote H or (C₁-C₃) alkyl; Q⁵, unsubstituted or substituted with one or more T³, denotes (C₁-C₃) alkyl; (C₁-C₃) fluoroalkyl; - (CH₂)_n- (C₃-C₆) cycloalkyl; - (CH₂)_n- (C₃-C₆) cyclofluoroalkyl; - (CH₂)_n-(4-, 5- or 6-member heterocycle); or Q⁵ denotes a hydrogen atom; (CH₂)_pOQ⁶; -(CH₂)_q-CN; -(CH₂)_pOC(O)Q⁶; -(CH₂)_q-C(O)OQ⁶; -(CH₂)_p-OC(O)OQ⁶; -(CH₂)_p-OC(O)NQ⁶Q⁷; -(CH₂)_q-C(O)NQ⁶Q⁷; -(CH₂)_q-C(O)NQ⁶OQ⁷; -(CH₂)_q-C(O)NQ⁶-NQ⁶Q⁷; -(CH₂)_p-NQ⁶C(O)Q⁷; -(CH₂)_pNQ⁶S(O)₂Q⁷; -(CH₂)_pNQ⁶S(O)₂NQ⁶Q⁷; -(CH₂)_p-NQ⁶C(O)OQ⁶; -(CH₂)_p-NQ⁶C(O)NQ⁶Q⁷; -(CH₂)_pNQ⁶Q⁷; -(CH₂)_p-NH-C(NHQ³)=NQ⁴; -(CH₂)_p-NH-CH=NQ³; (CH₂)_q-C(NHQ³)=NQ⁴; T¹ independently denotes a fluorine atom; -(CH₂)_nOQ¹; -(CH₂)_n-CN; -(CH₂)_nOC(O)Q¹; -(CH₂)_n-C(O)OQ¹; -(CH₂)_n-OC(O)OQ¹; -(CH₂)_n-OC(O)NHQ¹; -(CH₂)_n-C(O)NHQ¹; -(CH₂)_n-C(O)NHOQ¹; -(CH₂)_n-C(O)NH-NHQ¹; -(CH₂)_n-C(O)O-NHQ¹; -(CH₂)_n-NHC(O)Q¹; -(CH₂)_nNHS(O)₂Q¹; -(CH₂)_nNHS(O)₂NQ¹Q²; -(CH₂)_n-NHC(O)OQ¹; -(CH₂)_n-NHC(O)NQ¹Q²; -(CH₂)_nNHQ¹; -(CH₂)_n-NH-C(NHQ³)=NQ⁴; -(CH₂)_n-NH-CH=NQ³; (CH₂)_n-C(NHQ³)=NQ⁴; or T¹, unsubstituted or substituted with one or more T², independently denotes (C₁-C₃) alkyl; (C₁-C₃) fluoroalkyl; O- (C₁-C₃) fluoroalkyl; - (CH₂)_n- (4-, 5- or 6-membered aromatic, saturated, completely or partially unsaturated heterocycle containing at least one N); T² independently denotes OH, NH₂, CONH₂; T³ independently denotes H, F; (C₁-C₃) alkyl; (C₁-C₃) fluoroalkyl; O- (C₁-C₃) fluoroalkyl; - (CH₂)_nOQ⁶- (CH₂)_n- (C₃-C₆) cycloalkyl; - (CH₂)_n- (C₃-C₆) cyclofluoroalkyl; - (CH₂)_n-heterocycle; -(CH₂)_n-CN; -(CH₂)_nOC(O)Q⁶; -(CH₂)_n-C(O)OQ⁶; -(CH₂)_n-OC(O)OQ⁶; -(CH₂)_n-OC(O)NQ⁶Q⁷; -(CH₂)_n-C(O)NQ⁶Q⁷; -(CH₂)_n-C(O)NQ⁶OQ⁷; -(CH₂)_n-C(O)NQ⁶-NQ⁶Q⁷; -(CH₂)_n-C(O)O-NHQ⁶; -(CH₂)_n-NQ⁶C(O)Q⁷; -(CH₂)_nNQ⁶S(O)₂Q⁷; -(CH₂)_nNQ⁶S(O)₂NQ⁶Q⁷; -(CH₂)_n-NQ⁶C(O)OQ⁷; -(CH₂)_n-NQ⁶C(O)NQ⁶Q⁷; -(CH₂)_nNQ⁶Q⁷; -(CH₂)_n-NH-C(NHQ³)=NQ⁴; -(CH₂)_n-NH-CH=NQ³; -(CH₂)_n-C(NHQ³)=NQ⁴; Q⁶ and Q⁷ independently denoted by H; (C₁-C₃) alkyl; -(CH₂)_pNHQ³; -(CH₂)_p-NH-C(NHQ³)=NQ⁴; (CH₂)_p-NH-CH=NQ³; (CH₂)_q-C(NHQ³)=NQ⁴; -(CH₂)_pOQ³; -(CH₂)_qC(O)NQ³Q⁴; -(CH₂)_n-(4-, 5- or 6-membered aromatic, saturated, completely or partially unsaturated heterocycle containing at least one nitrogen atom); or Q⁶, Q⁷ and the nitrogen atom to which they are attached form together a saturated or partially unsaturated 4-, 5- or 6-member heterocycle containing 1, 2 or 3 heteroatoms; m has same or different values and independently denotes 1 or 2; n has identical or different values and independently denotes 0, 1, 2 or 3; p has same or different values and independently denotes 2 or 3; q has identical or different values and independently denotes 1, 2 or 3; wherein any carbon atom present in the group, selected from alkyl, cycloalkyl, fluoroalkyl, cyclofluoroalkyl and heterocycle, can be oxidised to form a C = O group; any sulfur atom present in the heterocycle can be oxidised to form a group S = O or a group S(O)₂; any nitrogen atom present in the heterocycle, or present in the group in which it is trisubstituted, thereby forming a tertiary amino group, can be further quaterised with a methyl group; and its racemate, enantiomer, diastereomer, geometrical isomer or pharmaceutically acceptable salt.

EFFECT: presented is a novel compound, a pharmaceutical composition based thereon, including a kit thereof, effective for use in treating or preventing bacterial infection.

20 cl, 7 ex, 4 tbl